Correction: Corrigendum: Long term outcome of Aldosteronism after target treatments

Authors :: Lian-Yu Lin
Likwang Chen
Ya-Hui Hu
Chia-Hui Chang
Kwan-Dun Wu
Shuo-Meng Wang
Vin-Cent Wu
Yen-Hung Lin
Shih-Chieh Jeff Chueh
Source :: Scientific Reports. 7
Publication Year :: 2017
Publisher :: Springer Science and Business Media LLC, 2017.
Abstract: Scientific Reports 6: Article number: 32103; published online: 02 September 2016; updated: 24 March 2017 The original version of this Article contained an error in the Abstract. “While need for receptor antagonist (MRA) MRA after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5and 50 mg may alleviate risk of death in a U-shape pattern”.

Subjects :: Pediatrics
medicine.medical_specialty
Multidisciplinary
business.industry
MEDLINE
Outcome (game theory)
eye diseases
Term (time)
Text mining
Defined daily dose
cardiovascular system
medicine
cardiovascular diseases
Risk of death
business
circulatory and respiratory physiology

Tools